VTRS News and Press, Viatris Inc. From 04/04/24

2024-04-04 08:55:15 ET More on Viatris Viatris Stock Is Still Worth Buying Viatris Inc. (VTRS) R&D Event (Transcript) Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued Teva and Viatris revive chance to dispute J&J's schizophrenia dr...

2024-04-01 12:17:16 ET NYSE: TEVA NASDAQ: VTRS NYSE: JNJ More on Johnson & Johnson, Teva Pharmaceutical, etc. Viatris Stock Is Still Worth Buying With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Viatris Inc. (VTRS) R&...

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. comme...

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States PR Newswire PITTSBURGH , April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of ...

2024-03-30 01:59:08 ET Summary Viatris Inc. stock has risen by 26.7% since my November 2023 bullish call, outperforming the S&P 500 Index. It's time to update my thesis - read on. Although net sales declined (as did EBITDA and net profit) in 2023, we saw an improvement in the ...

2024-03-28 13:49:05 ET More on Invesco S&P 500 Equal Weight ETF: RSP: Equal Weighting The S&P 500 To Minimize Magnificent Seven Exposure Is Not Optimal RSP: I Firmly Believe In An Allocation To Equal-Weight At This Juncture RSP: Happy 2024! Don't Make Decisio...

2024-03-27 15:26:02 ET Viatris Inc. (VTRS) R&D Event March 27, 2024 10:00 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott A. Smith - Chief Executive Officer Rajiv Malik - President Philippe Martin - Chief R&D Officer Dee...

Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeli...

2024-03-14 13:43:27 ET More on iShares Russell 1000 Growth ETF: IWF ETF: Solid Track Record, But Looks Overextended Now IWF: Price Isn't Everything; Favor Growth Over Value 10 option overwriting calls that can capture 7% upside - BofA These stocks could be at...

2024-03-14 09:53:00 ET Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around generic drugs. But while its operations are diverse, this i...